[{"address1": "60 rue de Wattignies", "city": "Paris", "zip": "75012", "country": "France", "phone": "33 1 40 26 04 70", "fax": "33 1 40 26 04 44", "website": "https://www.nanobiotix.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Laurent  Levy Ph.D.", "age": 50, "title": "Co-Founder, President of the Executive Board & CEO", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 764929, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bart  Van Rhijn", "age": 50, "title": "CFO & Member of Executive Board", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 673446, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Anne-Juliette  Hermant M.A.", "age": 49, "title": "Chief People Officer & Member of Executive Board", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 380286, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Louis  Kayitalire M.D.", "age": 65, "title": "Chief Medical Officer", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 536623, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Earl J. Bergey Ph.d.", "age": 68, "title": "Co-Founder", "yearBorn": 1955, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alain  Dostie", "title": "Chief Operating Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Craig  West CFA", "title": "Senior Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brandon  Owens", "title": "VP of Strategic Marketing & Corporate Communication", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Patrick  Tricoli M.B.A., Pharm.D.", "title": "Global Head of Business Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Margaret  Galluzzi", "title": "VP & Global Head of Clinical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 7, "compensationRisk": 10, "shareHolderRightsRisk": 7, "overallRisk": 9, "governanceEpochDate": 1714348800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 5.81, "open": 5.83, "dayLow": 5.71, "dayHigh": 5.84, "regularMarketPreviousClose": 5.81, "regularMarketOpen": 5.83, "regularMarketDayLow": 5.71, "regularMarketDayHigh": 5.84, "beta": 1.252, "forwardPE": -2.3174603, "volume": 1116, "regularMarketVolume": 1116, "averageVolume": 29749, "averageVolume10days": 36490, "averageDailyVolume10Day": 36490, "marketCap": 276908288, "fiftyTwoWeekLow": 1.87, "fiftyTwoWeekHigh": 11.0, "priceToSalesTrailing12Months": 7.6477103, "fiftyDayAverage": 6.24206, "twoHundredDayAverage": 7.158, "currency": "USD", "enterpriseValue": 149448768, "profitMargins": -1.09644, "floatShares": 22692136, "sharesOutstanding": 47111200, "sharesShort": 50275, "sharesShortPriorMonth": 48291, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.0011, "heldPercentInstitutions": 0.19685, "shortRatio": 0.78, "impliedSharesOutstanding": 47415800, "bookValue": -0.048, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -39700000, "trailingEps": -1.16, "forwardEps": -2.52, "enterpriseToRevenue": 4.128, "enterpriseToEbitda": -5.701, "52WeekChange": 1.9494948, "SandP52WeekChange": 0.23099434, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "NBTX", "underlyingSymbol": "NBTX", "shortName": "Nanobiotix S.A.", "longName": "Nanobiotix S.A.", "firstTradeDateEpochUtc": 1607697000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "eaa89785-6330-34d6-a007-8a168e42ba35", "messageBoardId": "finmb_20950715", "gmtOffSetMilliseconds": -14400000, "currentPrice": 5.84, "targetHighPrice": 12.91, "targetLowPrice": 11.01, "targetMeanPrice": 12.01, "targetMedianPrice": 12.12, "recommendationMean": 1.3, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 3, "totalCash": 75283000, "totalCashPerShare": 1.956, "ebitda": -26213000, "quickRatio": 1.509, "currentRatio": 1.751, "totalRevenue": 36208000, "revenuePerShare": 0.985, "returnOnAssets": -0.21783, "freeCashflow": -9401750, "operatingCashflow": -12476000, "revenueGrowth": 8.549, "grossMargins": 1.0, "ebitdaMargins": -0.72396004, "operatingMargins": -0.04262, "financialCurrency": "EUR", "trailingPegRatio": null, "__fetch_time": "2024-05-01"}]